Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

dual tasking

- PMLiVE

Third strike for BMS’ Opdivo in brain cancer

Despite failing first endpoint, trial is set to continue

- PMLiVE

Bedrock creates waves

The Bedrock team were awash with ideas at their summer watersports and BBQ event. All were Bravely Bedrock in a host of activities – including wakeboarding, paddle boarding and taming...

Bedrock Healthcare Communications

Celebrating Ten Magical Years with Clare Reynolds

Lucid loves to recognise and celebrate the magic people create for their clients, teams and patients. This month it was time to recognise the outstanding contribution that Clare Reynolds has...

Lucid Group Communications Limited

- PMLiVE

MSD’s Keytruda catches up in kidney cancer

Combination therapy approved in EU for all risk groups

- PMLiVE

Origin opens new facility in Alderley Park

Plans to support UK pharma start-ups

- PMLiVE

Pharma ranks bottom in Gallup poll of industry reputation

US opioid epidemic and medicine pricing to blame

- PMLiVE

Boehringer bolsters KRAS push with $720m Lupin deal

Signs of progress in the field are emerging

- PMLiVE

New hires at Bayer, Eisai and Accord Healthcare

The latest movers in pharma

- PMLiVE

Vertex eyes type 1 diabetes cure with biotech acquisition

Will acquire Semma Therapeutics for $950m

- PMLiVE

NICE backs NHS use of Novartis’ gene therapy Luxturna

First and only therapy for rare, inherited form of blindness

- PMLiVE

Indegene acquires DT Associates

Provides end-to-end enterprise solution for customer excellence – from consulting to operations

Building the Lucid Group Brand

Dennis O'Brien, Lucid Group CEO, discusses how they will grow the organisation and develop the Lucid Group brand over the next twelve years.

Lucid Group Communications Limited

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links